Free Trial

Goldman Sachs Group Inc. Boosts Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals logo with Medical background

Goldman Sachs Group Inc. boosted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 136.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,061,967 shares of the biotechnology company's stock after buying an additional 613,067 shares during the period. Goldman Sachs Group Inc. owned approximately 0.86% of Arrowhead Pharmaceuticals worth $32,496,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. FMR LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 58.2% in the third quarter. FMR LLC now owns 4,308,903 shares of the biotechnology company's stock valued at $115,780,000 after buying an additional 1,584,425 shares in the last quarter. Invesco Ltd. boosted its holdings in Arrowhead Pharmaceuticals by 9.6% during the 3rd quarter. Invesco Ltd. now owns 2,443,038 shares of the biotechnology company's stock worth $65,644,000 after acquiring an additional 214,618 shares during the last quarter. Norges Bank purchased a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at about $40,451,000. Capital International Investors lifted its position in shares of Arrowhead Pharmaceuticals by 55.2% during the fourth quarter. Capital International Investors now owns 1,277,560 shares of the biotechnology company's stock valued at $39,093,000 after purchasing an additional 454,631 shares in the last quarter. Finally, Avoro Capital Advisors LLC boosted its holdings in Arrowhead Pharmaceuticals by 100.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 1,130,000 shares of the biotechnology company's stock worth $34,578,000 after purchasing an additional 565,000 shares during the last quarter. Institutional investors own 62.61% of the company's stock.


Analysts Set New Price Targets

ARWR has been the topic of several recent analyst reports. HC Wainwright reissued a "buy" rating and set a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, June 11th. Cantor Fitzgerald reissued an "overweight" rating on shares of Arrowhead Pharmaceuticals in a research report on Thursday. Morgan Stanley reduced their price objective on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an "equal weight" rating for the company in a research note on Monday, May 13th. The Goldman Sachs Group started coverage on Arrowhead Pharmaceuticals in a research note on Wednesday, June 5th. They set a "neutral" rating and a $31.00 target price on the stock. Finally, Chardan Capital restated a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, June 3rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $47.89.

View Our Latest Stock Report on Arrowhead Pharmaceuticals

Insider Activity

In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total transaction of $41,934.69. Following the completion of the transaction, the director now owns 30,205 shares of the company's stock, valued at approximately $704,078.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.50% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR traded up $1.71 during trading on Friday, hitting $25.50. 3,479,143 shares of the company's stock traded hands, compared to its average volume of 961,486. The stock has a market capitalization of $3.17 billion, a price-to-earnings ratio of -6.00 and a beta of 0.94. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $20.67 and a 12-month high of $39.83. The business has a 50 day moving average of $24.08 and a 200-day moving average of $28.32.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. During the same quarter in the previous year, the firm earned $0.45 EPS. The business's quarterly revenue was down 100.0% on a year-over-year basis. On average, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.05 EPS for the current year.

Arrowhead Pharmaceuticals Profile

(Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Featured Articles

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Should you invest $1,000 in Arrowhead Pharmaceuticals right now?

Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

4 Best Tech Stocks to Own in 2024

4 Best Tech Stocks to Own in 2024

In this video, we explore the recent selloff and rotation of investments from NVDA to other Magnificent 7 stocks. Our analysts highlight four standout stocks—Amazon, Apple, Meta, and Alphabet.

Related Videos

The Best Single Stock to Own for 5 Years
NVIDIA Tops Microsoft and Apple for Most Valuable Company
3 Strong Buy Stocks for a Summer Surge

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines